XenoPort, Glaxo end collaboration on restless legs syndrome drug – Reuters UK

by admin on November 11, 2012

XenoPort, Glaxo end collaboration on restless legs syndrome drug
Reuters UK
(Reuters) – XenoPort Inc (XNPT.O) said it agreed with its marketing partner GlaxoSmithKline (GSK.L) (GSK.N) to end their collaboration on Horizant, a drug to treat restless legs syndrome. Glaxo will return all rights to the drug to XenoPort by April 30
GSK, XenoPort part ways after Horizant disappointmentFiercePharma
XenoPort and GlaxoSmithKline Mutually Agree to Terminate Their Collaboration The Herald | HeraldOnline.com

all 29 news articles »

View full post on restless leg syndrome – Google News

Leave a Comment

Previous post:

Next post: